Key data reveals for the small players
Praxis, Proqr and Nordic Nanovector are awaiting important data.
Novartis eyes up another gene therapy
The company is making a high-risk, high-reward bet with the purchase of Gyroscope.
Aldeyra needs more Tranquility
A pivotal failure sees the group tinker with a second phase 3 trial, and the delay looks like good news for Bausch.
Go or no go? Roche’s fresh start for a new year
2022 kicks off with key FDA decisions for Roche, Novartis and Pfizer, while Astrazeneca hopes to extend Lynparza even further.
Go or no go? UCB bids to make a mark in psoriasis
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Editas falls well short of Brilliance
Data on five patients treated with the Crispr therapy EDIT-101 raise doubts about efficacy and safety.
